PDR API
v1 Documentation
Access structured compound data, evidence grades, safety signals, and peer-reviewed references programmatically. Embed PDR content into your telehealth platform, patient portal, or clinical workflow.
Live
https://peptidedeskreference.com/api/v1/48
Compounds
130+
References
14
Safety Signals
Endpoints
GET
/api/v1/compoundsList all compounds with optional filtering
Query Parameters
categorystringFilter by category (e.g., Metabolic/GLP-1, Recovery, GH-axis)statusstringFilter by regulatory status (e.g., FDA-approved, Grey-market)gradestringFilter by evidence grade (A, B, C, D)qstringSearch by name or synonymlimitnumberResults per page (max 100, default 50)offsetnumberPagination offset (default 0)GET
/api/v1/compounds/:slugGet a full compound monograph by slug
Example Response
GET /api/v1/compounds/bpc-157 returns a full monograph:
{
"object": "compound",
"slug": "bpc-157",
"name": "BPC-157",
"synonyms": ["Body Protection Compound-157", "Bepecin"],
"category": "Recovery",
"status": "Grey-market",
"evidence_grade": "C",
"mechanism_tags": ["BPC Analogue"],
"use_case_tags": ["Injury Recovery", "Tissue Repair", "Gut Health"],
"overview": {
"clinical": "BPC-157 is a synthetic pentadecapeptide...",
"lay": "BPC-157 is a lab-made peptide based on..."
},
"mechanism_summary": "BPC-157 appears to exert tissue-protective...",
"evidence_summary": "The evidence base consists almost entirely...",
"safety": {
"summary": "No serious adverse events have been...",
"contraindications": ["Known hypersensitivity", ...],
"adverse_events": ["Injection site irritation", ...],
"interactions": ["No formal interaction studies exist", ...],
"signals": [
{
"name": "FDA compounding ban (2023)",
"severity": "High",
"notes": "In 2023, the FDA added BPC-157..."
}
]
},
"references": [
{
"type": "review",
"title": "Stable Gastric Pentadecapeptide BPC 157...",
"authors": "Sikiric P, Seiwerth S, Rucman R, et al.",
"year": 2014,
"source": "Current Pharmaceutical Design"
}
],
"meta": {
"last_reviewed_date": "2024-12-10",
"version": 1
}
}Need API access for your platform?
The API is currently open for evaluation. For production access with higher rate limits, SLA guarantees, and white-label embedding rights, contact us to discuss enterprise terms.